- Trials with a EudraCT protocol (86)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
86 result(s) found for: Blood Volume Determination.
Displaying page 1 of 5.
EudraCT Number: 2008-004175-22 | Sponsor Protocol Number: HC-G-H-0803 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:B. Braun Melsungen AG | |||||||||||||
Full Title: PROSPECTIVE, CONTROLLED, DOUBLE-BLIND, RANDOMIZED MULTICENTRIC STUDY ON THE EFFICACY AND SAFETY OF A TARGET CONTROLLED PLASMA VOLUME REPLACEMENT THERAPY WITH A HYPER-ONCOTIC BALANCED HES 130/0.42... | |||||||||||||
Medical condition: Intraoperative plasma volume replacement requirement in elective surgery of the pancreatic head (pylorus preserving pancreatic-duodenectomy, PPPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001920-36 | Sponsor Protocol Number: NIMAO/2018-01/JF-01 | Start Date*: 2020-12-03 | |||||||||||
Sponsor Name:CHU de NIMES | |||||||||||||
Full Title: Phase II a study to evaluate the safety, tolerability, distribution and dose effect of neoadjuvant doxorubicin arterial embolization in patients with prostate cancer at high risk of recurrence befo... | |||||||||||||
Medical condition: patients with high-risk prostate cancer with a Gleason score of 9-10 on biopsy,multimodal treatment radical prostatectomy validated in CPR, managed in Hospital of Nîmes. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005499-16 | Sponsor Protocol Number: 2013-624 | Start Date*: 2014-01-31 | |||||||||||||||||||||
Sponsor Name:Rigshospitalet, 2121 | |||||||||||||||||||||||
Full Title: Pilot Study with Treatment of Short Bowel Syndrome Patients with end-jejunostomi with the Glucagon-Like Peptide-1 analogue, Liraglutide (Victoza®) | |||||||||||||||||||||||
Medical condition: Short Bowel Syndrome with intestinal failure (SBS IF) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-004800-71 | Sponsor Protocol Number: 1230_OPBG_2016 | Start Date*: 2017-04-07 |
Sponsor Name:Bambino Gesù Children's Hospital | ||
Full Title: Determination of intraoperative levels of Cefoxitin during cardiac surgery requiring cardiopulmonary bypass in neonates, infants, children below, and above 40 kg. | ||
Medical condition: Antibiotic prophylaxis for surgical procedure using cardiopulmonary bypass in children with congenital heart disease. | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001151-40 | Sponsor Protocol Number: CTU148N | Start Date*: 2019-07-09 |
Sponsor Name:RIEMSER Pharma GmbH | ||
Full Title: Phase II pilot study: To determine an effective and tolerable dose of Hylase® "Dessau" (bovine hyaluronidase) in the treatment of hyaluronic acid filler overshoots by injection into defined areas o... | ||
Medical condition: In this study, healthy subjects get an artificial over-injection with Hyaluron acid filler on the back of the hands. To demonstrate the effectiveness of hylase® "Dessau" as an antidote for hyaluro... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2012-005330-10 | Sponsor Protocol Number: 987654321 | Start Date*: 2013-03-14 |
Sponsor Name:Erasmus University Medical Centre | ||
Full Title: Maternal pharmacokinetics and pharmacodynamics of nicardipine (iv) during treatment of severe hypertension in pregnancy. | ||
Medical condition: Pregnant patients with preeclampsia (hypertension and protein/creatinine ratio ≥ 30mg/mmol or ≥ 300mg protein/24hours) complicated with severe hypertension (systolic bloodpressure ≥ 160mmHg and/or ... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001016-30 | Sponsor Protocol Number: NODAGA-RGD-2 | Start Date*: 2018-12-11 |
Sponsor Name:Department of Nuclear Medicine, Medical University Innsbruck | ||
Full Title: PROSPECTIVE STUDY OF 68GA-NODAGA-RGD-PET FOR THE NON-INVASIVE DETERMINAITON OF THE INTEGRIN αvβ3 EXPRESSION IN PATIENTS WITH UNTREATED OR RECURRENT BREAST CANCER, COLORECTAL CANCER, NON-SMALL CELL ... | ||
Medical condition: Patient with untreated or reccurent breast cancer, non-small cell lung cancer, colorectal cancer and neuroendocrine tumors | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-002685-20 | Sponsor Protocol Number: BI3023_3002 | Start Date*: 2011-11-24 | |||||||||||
Sponsor Name:CSL Behring GmbH | |||||||||||||
Full Title: REPLACE (Randomized evaluation of fibrinogen versus placebo in complex cardiovascular surgery): a prospective, multinational, multicenter, randomized, double-blind, placebo-controlled, phase III... | |||||||||||||
Medical condition: Acute bleeding while undergoing aortic replacement surgery | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) FI (Completed) IT (Completed) AT (Completed) CZ (Completed) PL (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004958-34 | Sponsor Protocol Number: UNOLE0457 | Start Date*: 2015-01-30 |
Sponsor Name:University of Leicester | ||
Full Title: Midazolam Measurement and Modelling using Matrix Samplers | ||
Medical condition: Not applicable | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-005776-24 | Sponsor Protocol Number: MRY-IIA-2015-01 | Start Date*: 2016-10-27 | |||||||||||
Sponsor Name:Dr. Manuel Rodríguez Yáñez | |||||||||||||
Full Title: Intensive treatment of blood pressure in acute ischemic stroke. TICA 2 study. | |||||||||||||
Medical condition: Acute ischemic stroke | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000791-42 | Sponsor Protocol Number: JVM-GLU-12 | Start Date*: 2012-07-26 |
Sponsor Name:FUNDACION INVESTIGACION BIOMEDICA HOSPITAL UNIVERSITARIO LA PRINCESA | ||
Full Title: OPEN, RANDOMIZED AND CONTROLLED STUDY OF SAFETY AND VIABILITY, TO EVALUATE THE NEUROPROTECTIVE EFFECT OF PLASMA GLUTAMATE DIALYSIS IN ACUTE ISCHEMIC STROKE. | ||
Medical condition: BRAIN ISCHEMIC STROKE IN ACUTE PHASE | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-001327-41 | Sponsor Protocol Number: IMIB-RMV-2021-02 | Start Date*: 2021-07-12 |
Sponsor Name:Fundación para la formación e investigación sanitarias de la Región de Murcia | ||
Full Title: Withdrawal of pharmacological treatment in patients responding to cardiac resynchronization therapy: Open and randomized study | ||
Medical condition: Heart failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-003998-28 | Sponsor Protocol Number: CER-001-CLIN-003 | Start Date*: 2012-01-24 | |||||||||||
Sponsor Name:Cerenis Therapeutics | |||||||||||||
Full Title: Modifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-Label Study of the Effects of CER-001 on Plaque Volume in Subjects with Homozygous Familial Hypercholesterolemia (HoFH) | |||||||||||||
Medical condition: homozygous familial hypercholesterolemia | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002484-26 | Sponsor Protocol Number: FIDEL | Start Date*: 2014-08-18 | |||||||||||
Sponsor Name:LFB Biomédicaments | |||||||||||||
Full Title: A RANDOMISED, MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ON THE EFFICACY AND SAFETY OF A THERAPEUTIC STRATEGY OF POST PARTUM HAEMORRHAGE COMPARING EARLY ADMINISTRATION OF HUMAN FIBRINOGEN ... | |||||||||||||
Medical condition: post partum haemorrhage following vaginal delivery | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019587-36 | Sponsor Protocol Number: DSHNHL2009-1 | Start Date*: 2011-10-10 | |||||||||||
Sponsor Name:Universität des Saarlandes | |||||||||||||
Full Title: Improvement of outcome and reduction of toxicity in elderly patients with CD20+ aggressive B-cell lymphoma by an optimised schedule of the monoclonal antibody rituximab, substitution of conventiona... | |||||||||||||
Medical condition: Diffuse large B-cell lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002221-29 | Sponsor Protocol Number: VIT-2763-THAL-201 | Start Date*: 2020-02-25 | |||||||||||
Sponsor Name:Vifor (International) Inc. | |||||||||||||
Full Title: A Phase 2a, Double-blind, Randomised, Placebo-controlled, Parallel Group, Multicentre Study on Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Multiple Doses of... | |||||||||||||
Medical condition: Non-transfusion Dependent Beta-thalassaemia. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001760-29 | Sponsor Protocol Number: ALCOVID-19 | Start Date*: 2020-09-09 |
Sponsor Name:Sociedad Española de Farmacia Hospitalaria | ||
Full Title: Phase II clinical trial to evaluate the efficacy and safety of inhaled ethanol in the treatment of early-stage COVID-19. | ||
Medical condition: COVID-19 | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2010-019415-38 | Sponsor Protocol Number: CZOL446HDE38T | Start Date*: 2011-03-23 | |||||||||||
Sponsor Name:Universitätsklinikum Würzburg | |||||||||||||
Full Title: A prospective, bicentric, randomised, primarily double blind, placebo-controlled study to evaluate the efficacy of zoledronic acid for the treatment of bone marrow syndrome | |||||||||||||
Medical condition: Determination of efficacy of Zoledronic Acid on the treatment of bone marrow edema syndrome. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002619-89 | Sponsor Protocol Number: B1761031 | Start Date*: 2019-06-05 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A SINGLE ARM, OPEN-LABEL, PHASE 4 STUDY EVALUATING QT INTERVAL, PHARMACOKINETICS, AND SAFETY OF GEMTUZUMAB OZOGAMICIN (MYLOTARG™) AS A SINGLE-AGENT REGIMEN IN PATIENTS WITH RELAPSED OR REFRACTOR... | |||||||||||||
Medical condition: relapsed or refractory CD33-positive acute myeloid leukaemia (AML) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) PL (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002806-10 | Sponsor Protocol Number: SOBI003-001 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Swedish Orphan Biovitrum AB (publ) | |||||||||||||
Full Title: An open, non-controlled, parallel, ascending multiple-dose, multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of SOBI003 in pediatric MPS IIIA patients | |||||||||||||
Medical condition: Mucopolysaccharidosis Type IIIA or Sanfilippo Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.